Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis
Blau syndrome is a systemic autoinflammatory granulomatous disease caused by mutations in the nucleotide-binding oligomerization domain 2 (NOD2) gene. NOD2 is an intracellular pathogen recognition receptor. Upon binding to muramyl dipeptide (MDP), NOD2 activates the NF-κB pathway, leading to the upr...
Main Authors: | Tomoko Matsuda, Naotomo Kambe, Riko Takimoto-Ito, Yoko Ueki, Satoshi Nakamizo, Megumu K. Saito, Syuji Takei, Nobuo Kanazawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.895765/full |
Similar Items
-
Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome
by: Yoko Ueki, et al.
Published: (2023-06-01) -
<i>NOD</i>2 Mutation-Associated Case with Blau Syndrome Triggered by BCG Vaccination
by: Akiko Arakawa, et al.
Published: (2021-02-01) -
Incomplete penetrance of NOD2 C483W mutation underlining Blau syndrome
by: Shao-Yu Chang, et al.
Published: (2022-10-01) -
Sustained Surface ICAM-1 Expression and Transient PDGF-B Production by Phorbol Myristate Acetate-Activated THP-1 Cells Harboring Blau Syndrome-Associated <em>NOD2</em> Mutations
by: Mizuho Nishiyama, et al.
Published: (2021-04-01) -
Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function
by: Liming Mao, et al.
Published: (2022-09-01)